UBS maintains Zimmer Biomet Holdings at Buy, raises price target to $130 from $120

UBS kept its Buy rating on Zimmer Biomet Holdings and increased its price target to $130 from $120, suggesting a 21.7% upside from the Nov 5 close of $106.85. Recent analyst price targets for the company range from $107 to $125.

Original reporting
Published Nov 6, 2026, 12:51 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 12:55 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
UBS maintains Zimmer Biomet Holdings at Buy, raises price target to $130 from $120 — source image
Decision brief

The 30-second read

$ZBHBullishMed
01

Why it matters

UBS's price target increase may prompt short-term buying, but without fresh operational news the effect could be muted.

02

Market read

Analyst target raise is a modest catalyst for ZBH, offering a short-term upside opportunity.

03

What to watch

No new product or earnings data accompanies the upgrade; price may already reflect optimism.

Relevance 6/10Novelty 5/10Timing: today

Background

Zimmer Biomet is a leading orthopedic implant manufacturer. Analyst upgrades often move the stock modestly.

Company-level read

Ticker impact

$ZBHBullishHigh confidence
Context

UBS upgraded Zimmer Biomet Holdings to Buy and raised its price target to $130 from $120.

Expected impact

likely upward pressure as investors price in the higher target.

Evidence & confidence

Target increase of 8.3% signals improved outlook; no other catalysts present.

Market effects

May lift sentiment for the broader orthopedic device sector.

U.S. market focus; limited regional spillover.

Low global impact; primarily affects ZBH and peers.

Counterpoint

Target raise could be premature if upcoming earnings miss expectations.

Key entities

  • UBS

    Investment bank providing the rating upgrade.

  • Zimmer Biomet Holdings

    Orthopedic device maker (ticker ZBH).

Related articles

$ZBHMed

What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call

Zimmer Biomet (ZBH) reported Q3 sales growth of 13% in technology, bone cement, and surgical sales, but a 2.6% decline in global knee sales. CEO Tornos attributed knee underperformance to commercial execution. The company expects to launch its Monogram robotic system in early 2027. Q3 adjusted earnings were $1.90 per share, with margins declining but cash flow rising. Full-year sales growth guidance was raised to 4.4%-4.9%.

$ZBHMed

Truist raises Zimmer Biomet stock price target on robotics progress

Truist Securities raised Zimmer Biomet's (ZBH) price target to $114 from $106, citing 3.7% Q3 organic revenue growth, though EPS missed estimates. The stock is up 13% in a week. Analysts note progress in robotics and hip segments, but caution on knee division weakness and future risks. Other analysts also raised targets, with Stifel at $125 and Jefferies at $120.

$ZBHMed

Zimmer Biomet Holdings Inc (ZBH) (Q3 2026) Earnings Call Highlights: Guidance Raised as Hips

Zimmer Biomet (ZBH) reported Q3 2026 earnings, raising guidance despite a 2.6% decline in knee business due to sales force transition and competitive pressure. Adjusted operating margin fell 140 basis points to 25.1%, and gross margin decreased 90 basis points to 71.7%. CEO Ivan Tornos highlighted sustainable growth in hips and S.E.T. areas, but acknowledged underperformance in knees. China headwinds and sales force disruption pose risks.